Becton, Dickinson(US:BDX)2025-08-07 12:00Q3 FY25 Financial Performance - Adjusted revenue increased by 8.9% to $5.509 billion, with organic revenue growth of 3.0%[37] - Adjusted diluted EPS grew by 5.1% year-over-year to $3.68[26, 37] - Adjusted operating margin increased by 60 bps year-over-year to 25.8%[26] - Free cash flow decreased by 25% year-over-year to $1.667 billion YTD, impacted by increased inventory and tariff payments[39] Segment Performance - BD Medical revenue increased by 14.0% FXN to $2.927 billion, with 3.2% organic growth[26, 28] - BD Life Sciences revenue decreased by 1.1% FXN to $1.254 billion[26, 31] - BD Interventional revenue increased by 6.8% FXN to $1.328 billion[26, 33] FY25 Guidance - The company reaffirmed organic revenue growth guidance of 3.0% to 3.5%[17, 41] - Adjusted diluted EPS guidance increased to $14.30 to $14.45, reflecting 9.4% year-over-year growth at the midpoint[17, 41] - Estimated total company revenue is projected to be approximately $21.8 billion to $21.9 billion[41]